G
Gregory D. Lewis
Researcher at Harvard University
Publications - 269
Citations - 16752
Gregory D. Lewis is an academic researcher from Harvard University. The author has contributed to research in topics: Heart failure & Medicine. The author has an hindex of 52, co-authored 219 publications receiving 13161 citations. Previous affiliations of Gregory D. Lewis include Yale University & Pennington Biomedical Research Center.
Papers
More filters
Journal ArticleDOI
Metabolite profiles and the risk of developing diabetes
Thomas J. Wang,Martin G. Larson,Martin G. Larson,Ramachandran S. Vasan,Ramachandran S. Vasan,Susan Cheng,Susan Cheng,Susan Cheng,Eugene P. Rhee,Eugene P. Rhee,Elizabeth L. McCabe,Elizabeth L. McCabe,Gregory D. Lewis,Gregory D. Lewis,Caroline S. Fox,Caroline S. Fox,Paul F. Jacques,Céline Fernandez,Christopher J. O'Donnell,Christopher J. O'Donnell,Christopher J. O'Donnell,Stephen A Carr,Vamsi K. Mootha,Vamsi K. Mootha,Jose C. Florez,Jose C. Florez,Amanda Souza,Olle Melander,Clary B. Clish,Robert E. Gerszten,Robert E. Gerszten +30 more
TL;DR: Findings underscore the potential key role of amino acid metabolism early in the pathogenesis of diabetes and suggest that amino acid profiles could aid in diabetes risk assessment.
Journal ArticleDOI
Effect of phosphodiesterase-5 inhibition on exercise capacity and clinical status in heart failure with preserved ejection fraction: A randomized clinical trial
Margaret M. Redfield,Horng H. Chen,Barry A. Borlaug,Marc J. Semigran,Kerry L. Lee,Gregory D. Lewis,Martin M. LeWinter,Jean L. Rouleau,David A. Bull,Douglas L. Mann,Anita Deswal,Lynne W. Stevenson,Michael M. Givertz Elizabeth O Ofili,Michael M. Givertz Elizabeth O Ofili,Christopher M. O'Connor,G. Michael Felker,Steven R. Goldsmith,Bradley A. Bart,Steven McNulty,Jenny C. Ibarra,Grace Lin,Jae K. Oh,Manesh R. Patel,Raymond J. Kim,Russell P. Tracy,Eric J. Velazquez,Kevin J. Anstrom,Adrian F. Hernandez,Alice M. Mascette,Eugene Braunwald +29 more
TL;DR: Among patients with HFPEF, phosphodiesterase-5 inhibition with administration of sildenafil for 24 weeks, compared with placebo, did not result in significant improvement in exercise capacity or clinical status.
Journal ArticleDOI
Metabolite Profiling Identifies Pathways Associated With Metabolic Risk in Humans
Susan Cheng,Eugene P. Rhee,Martin G. Larson,Gregory D. Lewis,Elizabeth L. McCabe,Elizabeth L. McCabe,Dongxiao Shen,Melinda J. Palma,Lee D. Roberts,Andre Dejam,Amanda Souza,Amy Deik,Martin Magnusson,Caroline S. Fox,Caroline S. Fox,Christopher J. O'Donnell,Christopher J. O'Donnell,Christopher J. O'Donnell,Ramachandran S. Vasan,Olle Melander,Clary B. Clish,Robert E. Gerszten,Thomas J. Wang,Thomas J. Wang +23 more
TL;DR: Biochemical profiling identified circulating metabolites not previously associated with metabolic traits and experimentally interrogating one of these pathways demonstrated that excess glutamine relative to glutamate, resulting from exogenous administration, is associated with reduced metabolic risk in mice.
Journal ArticleDOI
Lipid profiling identifies a triacylglycerol signature of insulin resistance and improves diabetes prediction in humans
Eugene P. Rhee,Susan Cheng,Susan Cheng,Martin G. Larson,Geoffrey A. Walford,Gregory D. Lewis,Gregory D. Lewis,Elizabeth L. McCabe,Elizabeth L. McCabe,Elaine Yang,Laurie A. Farrell,Caroline S. Fox,Caroline S. Fox,Christopher J. O'Donnell,Christopher J. O'Donnell,Steven A. Carr,Ramachandran S. Vasan,Jose C. Florez,Jose C. Florez,Clary B. Clish,Thomas J. Wang,Thomas J. Wang,Robert E. Gerszten,Robert E. Gerszten +23 more
TL;DR: A relationship between lipid acyl chain content and diabetes risk is identified and how lipid profiling could aid in clinical risk assessment is demonstrated.
Journal ArticleDOI
Sildenafil Improves Exercise Capacity and Quality of Life in Patients with Systolic Heart Failure and Secondary Pulmonary Hypertension
Gregory D. Lewis,Ravi V. Shah,Khurram Shahzad,Janice M. Camuso,Paul P. Pappagianopoulos,Judy Hung,Ahmed Tawakol,Robert E. Gerszten,David M. Systrom,Kenneth D. Bloch,Marc J. Semigran +10 more
TL;DR: In this article, the authors tested the hypothesis that sildenafil, an effective therapy for pulmonary arterial hypertension, would lower pulmonary vascular resistance and improve exercise capacity in patients with systolic heart failure complicated by secondary pulmonary hypertension.